Allogene Therapeutics, Inc. (ALLO) research: valuation against peers, fundamentals over time, risk and news coverage
ALLO
Allogene Therapeutics, Inc.No data in this window.
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
- BREAKING STORYBULLISHZipalertinib Hits Primary Endpoint in Lung Cancer Trial as Biotech Catalyst Season Delivers Mixed Reads
Zipalertinib met its primary endpoint in a lung cancer study, delivering a clean pivotal readout into an unusually crowded biotech catalyst window that also featured Definium Therapeutics' Phase 3 Voyage results for DT120 and quarterly updates from Allogene and Inovio.
Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.